Liu Jiafu, Zhi Xiao, Fang Xiaolan, Li Wenyao, Zhao Weixin, Liu Meng, Lai Enping, Fang Wenzhuo, Wang Juan, Zheng Yu, Zou Jiang, Fu Qiang, Cui Wenguo, Zhang Kaile
Department of Urology Affiliated Sixth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
School of Materials Science and Engineering Shanghai University of Engineering Science Shanghai China.
Smart Med. 2025 May 19;4(2):e70010. doi: 10.1002/smmd.70010. eCollection 2025 Jun.
The research of primary urological cancers, including bladder cancer (BCa), prostate cancer (PCa), and renal cancer (RCa), has developed rapidly. Microfluidic technology provides a good variety of benefits compared to the heterogeneity of animal models and potential ethical issues of human study. Microfluidic technology and its application with cell culture (e.g., organ-on-a-chip, OOC) are extensively used in urological cancer studies in preclinical and clinical settings. The application has provided diagnostic and therapeutic benefits for patients with urological diseases, especially by evaluating biomarkers for urinary malignancies. In this review, we go through the applications of OOC in BCa, Pca and Rca, and discuss the prospects of reducing the cost and improving the repeatability and amicability of the intelligent integration of urinary system organ chips.
包括膀胱癌（BCa）、前列腺癌（PCa）和肾癌（RCa）在内的原发性泌尿系统癌症的研究发展迅速。与动物模型的异质性和人体研究潜在的伦理问题相比，微流控技术具有诸多优势。微流控技术及其在细胞培养中的应用（例如，芯片上的器官，OOC）广泛应用于临床前和临床环境中的泌尿系统癌症研究。该应用为泌尿系统疾病患者提供了诊断和治疗方面的益处，特别是通过评估尿路上皮恶性肿瘤的生物标志物。在本综述中，我们阐述了OOC在BCa、Pca和Rca中的应用，并讨论了降低成本以及提高泌尿系统器官芯片智能集成的可重复性和适用性的前景。
